Michael Anthony White

Vice President and Chief Scientific Officer, Tumor Cell Biology
Media Name: mike_white_050418_300x170.jpg
  • Group: Oncology
  • Location: La Jolla, CA

I joined Pfizer in 2016 as CSO for Tumor Cell Biology, in the Oncology Research and Development Group. We are focused on the discovery and development of lead-in-class small molecule cancer therapies. Prior to Pfizer, I was Professor of Cell Biology; Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center; and inaugural Director of the Cancer Intervention and Prevention Discovery program at UT Southwestern Medical Center.

The research in my academic group over the past 20 years has helped define the nature of oncogenic cell regulatory networks; decode the molecular architecture of mitogenic signaling pathways; enrich functional annotation of cancer genomes; and deliver genomics-guided cancer intervention target nominations. This work has been described in ~150 publications with over 12,000 citations and an H-index of 65. (http://www.ncbi.nlm.nih.gov)


At Pfizer, our group pursues chemically addressable targets that intercept oncogenic signaling networks; modulate tumor/host interactions; and promote productive anti-tumor immune responses. We partner with colleagues in Medicinal Sciences, Drug Safety R&D, and Clinical Development to help deliver first-in-class small molecule drugs that benefit patient populations with unmet need.


  1. Mode of Action and Pharmacogenomic Biomarkers for Exceptional Responders to Didemnin B.Nature Chemical Biology. 2015; 11(6):401-8.
    Potts MB, McMillan EA, Rosales TI, Kim HS, Ou YH, Toombs JE, Brekken RA, Minden MD, MacMillan JB, White MA.https://www.ncbi.nlm.nih.gov/pubmed/25867045
  2. XPO1-Dependent Nuclear Export is a Druggable Vulnerability in KRAS-Mutant Lung Cancer.Nature. 2016; 538(7623):114-117.
    Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA.
  3. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery. 2017; 7(8):832-851.
    Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA.
  4. Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.
    Nature Communications. 2017; 8(1):2270.
    Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Olswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA.
  5. Chemistry-First Approach for Nomination of Biomarker-Driven Intervention Opportunities in Lung Cancer.
    Cell. 2018. In Press.
    McMillan EA, Ryu M-J, Diep CH, Mendiratta S, Clemenceau JR, Vaden RM, Kim J-H, Motoyaji T, Covington KR, Peyton M, Huffman K, Wu X, Girard L, Sung Y, Chen P-H, Mallipedi PL, Lee JY, Hanson J, Yu Y, Park S, Sudderth J, DeSevo C, Muzny DM, Doddapaneni HV, Gazdar A, Gibbs RA, Hwang TH, Heymach JV, Wistuba I, Coombes KR, Williams NS, Wheeler DA, MacMillan JB, Deberardinis RJ, Roth MG, Posner BA, Minna JD, Kim HS, White MA.


University of North Carolina, Chapel Hill, Biology, Ph.D., 1992
University of Iowa, Iowa City, Zoology, B.S., 1986


Hortense and Morton Sanger Professorship in Oncology, 2009
Sherry Wigley Crow Cancer Research Endowed Chair in Honor of R Kirby, M.D., 2009 – 2016
Grant A. Dove Distinguished Chair for Research in Oncology, 2011 – 2016
NCI Outstanding Investigator Award, 2015

Here at Pfizer, we participate in the ultimate transdisciplinary, multi-investigator, discovery and development campaign to deliver transformative therapies for patients that need them.